THE SILVER DRESSINGWITH MORE POSITIVES
formerly known as Exsalt™ Dressing
USE KERRACONTACT™ AG DRESSINGS ON CHRONIC AND ACUTE WOUNDS THAT ARE INFECTED OR AT RISK OF INFECTION
THE SILVER DRESSINGWITH MORE POSITIVES
Quickly Kills 99.999% of a broad spectrum of bacteria1
Disrupts and breaks down biofi lm to expose bacteria2
Kills bacteria for up to seven days1
Minimal stinging or pain3
Cost E� ective
THE POWER OF Ag OXYSALTS™ TECHNOLOGYSilver is only e� ective at killing bacteria when it is missing electrons and in an ionic state. The more electrons that are missing, the more positively charged the silver becomes. This leads to a greater ability of silver to disrupt the normal function of the bacteria4.
KerraContact™ Ag dressings with Ag Oxysalts™ Technology is designed with 3 missing electrons (Ag3+) to make it more e� ective at killing bacteria. Other silver dressings are only missing one electron (Ag1+), making their silver less e� ective4.
KerraContact™ Ag is a silver dressing for chronic and acute wounds that utilizes Ag Oxysalts™ Technology. Ag Oxysalts™ is a unique type of silver that delivers a quick 5 log bacteria kill rate while at the same time being gentle on patients and your budget.1-4 The result is a silver dressing with more positives.
Two outer layers of fl exible, non-adherent high-density polyethylene (HDPE)
Can be applied wet or dry, cut to shape to fi t wound area, and folded/shaped for cavities
Polyester inner layer o� ers absorbency and fl exibility
KerraContact™ Ag dressings can absorb fi ve times their own weight and are compatible with other secondary dressings, such as KerraFoam™ and KerraMax Care® dressings, if further absorption is required.
All layers are coated with Ag Oxysalts™ Technology
KERRACONTACT™ AG DRESSINGS ARE TOUGH ON BACTERIA TO HELP WOUNDS PROGRESS TOWARDS HEALING.1,2
KERRACONTACT™ AG DRESSINGS ARE GENTLE ON PATIENTS AND YOUR BUDGET
QUICKLY KILLS 99.999% OF A BROAD SPECTRUM OF BACTERIA1
DISRUPTS AND BREAKS DOWN in vitro BIOFILM TO EXPOSE BACTERIA2
Organisms tested to date:Gram-Negative• Acinetobacter baumannii• Escherichia coli• Pseudomonas aeruginosa• Klebsiella pneumoniae
Gram-Positive• Corynebacterium striatum• Enterococcus faecalis• Enterococcus faecalis VRE• Staphylococcus epidermidis• Staphylococcus aureus• Methicillin-resistant staphylococcus aureus (MRSA)
Fungus• Candida albicans• Aspergillus niger
1,000,000
100,000 1
2
3
4
5
10,000
1,000
100
10
1
Aquacel
Ag
Contro
l
Mepile
x Ag
Therab
ond 3D
Actico
at 7
Kerra
Contac
t™ A
g
Num
ber
of
Bac
tier
a/m
l
Log
Red
ucti
on
*4 hrs, 37°C, SWF, data on file
1
10
100
1,000
10,000
100,000
1,000,000
10,000,000
Ag3+
Ag Oxysalts™ Technology
Ag1+
Silver nitrate
Ag Ion Concentration [ppm]
0 17 34 50 67 100 135 150
P. a
erug
inos
a [
CF
U/m
L]
in vitro studies show Ag Oxysalts™ Technology disrupts and kills P. aeruginosa biofilm.
Molar concentrations of Ag Oxysalts™ Technology
were used to measure kill rates and to determine
e�cacy vs. biofilms after 24 hour exposure
using the Calgary biofilm device evaluating
MBEC and following the device manufacturer’s
protocol; biofilms were grown for 24 hours,
then confirmed and visualized using microscopy
and staining; e�cacy was demonstrated vs. P.
aeruginosa, S. aureus, and E. coli biofilms.
KILLS BACTERIA FOR UP TO 7 DAYS1
In a in vitro assay, KerraContact™ Ag dressings
were shown to maintain its antimicrobial
activity against a broad spectrum of bacteria
for up to 7 days. This reduces the need for frequent dressing
changes and unnecessary disturbance to the
wound.
KerraContact™ Ag
Re-innoculation
4 log reduction
1 2 3 4 5 6 7
7.0
6.0
5.0
4.0
3.0
2.0
1.0
0.0
Log
Bac
teri
al C
oun
t (1
0%
)
Days
Antibacterial activity*
Anti-bacterial Activity of Ag Oxysalts™ Technology within Established in vitro Biofilm
KERRACONTACT™ AG DRESSINGS ARE GENTLE ON PATIENTS AND YOUR BUDGET
MINIMAL STINGING OR PAIN VS. ACTICOAT®7 DRESSING3
COST EFFECTIVE
pH
leve
l
Time (minutes)15 30 45 60 90 120
6
7
8
9
10
11
12
13
14Acticoat® 7KerraContact™ Ag KerraCcontact™ dressings
demonstrated only a nominal shift in pH, at markedly lower silver
concentration compared to most
competitors. This means that patients
experience minimal pain, so that
comfort can be increased without
compromising on biocidal
e� ectiveness.
As Ag Oxysalts™ Technology is highly e� cacious, less silver is required in the dressing. This means the silver coatings
can be deposited more e� ciently on the dressing. This signifi cantly lowers production costs and results in a more
cost-e� cient solution. In fact, KerraContact™ Ag dressings o� er signifi cant cost savings in comparison to Acticoat®
7 dressings, over seven-day use.7 dressings, over seven-day use.
Order information
To place an order please contact your medical supply distributoror call 855-522-2211
*All photos are property of their respective owners.
Product code Size Dressings per boxPN-09-0102 2” x 2” 10
PN-09-0103 4” x 5” 10
PN-09-0104 4” x 8” 10
PN-09-0105 6” x 6” 10
PN-09-0106 6” x 9” 10
PN-09-0108 8” x 16” 10
PN-09-0116 16” x 16” 5
PN-09-0120 4” x 48” 5
PN-09-0132 16” x 32” 5
Crawford Healthcare Inc. | 2005 South Easton Rd. | Suite 203 | Doylestown, PA 18901Tel 855-522-2211 | Email [email protected]/us
KerraContact™ is a registered trademark of Crawford Healthcare. Ag Oxysalts™ is registered trademark of Exciton Technologies. All other trademarks are property of their respective owners. © Copyright Crawford Healthcare Ltd, 2015.
References: 1. Log reduction testing for Exsalt T7 Dressing.Data on fi le 2009, Crawford Healthcare Ltd. 2. Miller S. etal. Antimicrobial silver in medical devices: Composition and effi cacy. Poster presented at: Spring meeting of Symposia on Advanced Wound Care; May 2013; Denver, CO. 3. In vitro Cytotoxicity Evaluation: Mamalian Fibroblast Cells. Data on File. Crawford Healthcare Ltd. 4. Spina C. Silver I, II, III: Chemical Characteristics, Properties, and Anti-microbial Activity. Data on fi le. Crawford Healthcare Ltd.
CH14009-US-Rev1
Burn*
Diabetic Foot Ulcer* Surgical Wound* TENS, StevensJohnson Syndrome*
Leg Ulcer* Pressure Ulcer*
USE KERRACONTACT™ AG DRESSINGS ON CHRONIC AND ACUTE WOUNDS THAT ARE INFECTED OR AT RISK OF INFECTION